Dr. Reddy's Laboratories slides Friday, underperforms market
Dr. Reddy's Laboratories Ltd. closed 18.89% below its 52-week high of 1,420.20 rupees, which the company reached on August ...
Dr. Reddy's Laboratories rises Thursday, outperforms market
Dr. Reddy's Laboratories Ltd. closed 17.55% below its 52-week high of 1,420.20 rupees, which the company achieved on August ...
Allspring Global Investments Holdings LLC Acquires 427,573 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)
Allspring Global Investments Holdings LLC grew its holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY – Free Report) by ...
ETF Daily News4d
Savant Capital LLC Takes Position in Dr. Reddy’s Laboratories Limited (NYSE:RDY)
View Our Latest Report on Dr. Reddy’s Laboratories Dr. Reddy’s Laboratories Trading Down 0.3 % NYSE RDY opened at $13.57 on Wednesday. The company has a current ratio of 1.92, a quick ratio of ...
Hosted on MSN19d
Dr. Reddy’s Laboratories Engages with Investors in Upcoming Conferences
An announcement from Dr Reddy’s Laboratories ( ($RDY) ) is now available. On February 4, 2025, Dr. Reddy’s Laboratories announced its ...
Hosted on MSN19d
Dr. Reddy’s Laboratories to Engage with Investors in Mumbai Conference
Dr Reddy’s Laboratories ( ($RDY) ) has shared an update. On February 4, 2025, Dr. Reddy’s Laboratories announced its participation in an investor ...
Business Insider27d
Barclays Reaffirms Their Buy Rating on Dr Reddy’s Laboratories (RDY)
Barclays analyst Balaji Prasad maintained a Buy rating on Dr Reddy’s Laboratories (RDY – Research Report) today and set a price target of $17.00. The company’s shares closed last Friday at ...
Benzinga.com15d
Dr. Reddy's Laboratories Reports Strong Q3 & 9MFY25 Financial Results with Strategic Growth Trajectory
Dr. Reddy's Laboratories DRREDDY RDY has delivered a set of financial results. For the third quarter (Q3FY25) and the nine months (9MFY25) ending December 31, 2024, the company showcased robust ...
Business Wire17d
Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories SA, wholly-owned subsidiary of Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY ...
The Hindu16d
Dr. Reddy’s, Shanghai Henlius Biotech ink $131.6 million cancer drug deal
Dr. Reddy’s Laboratories will develop and commercialise Shanghai Henlius Biotech’s biosimilar candidate to Johnson & Johnson’s multiple myeloma drugs Darzalex and Darzalex Faspro.
Indiatimes16d
Dr Reddy's in pact with Shanghai Henlius Biotech for exclusive US, Europe rights for daratumumab biosimilar
To Pay Chinese player up to $131.6 million for subcutaneous & intravenous formulations of HLX15 “The agreement combines Dr Reddy’s global commercial presence with Henlius’ proven ...
Business Today3d
Vedanta, Dr Reddys Labs, Cyient: How to trade these three buzzing stocks
Dr Reddy's Labs has experienced a notable decline from its peak of Rs 1,406, nearing the key support level of Rs 1,120, which has historically acted as a strong floor, often triggering a pullback.